THE DEAL, AT A GLANCE
From the announcementAdvanCell
01What it doesWith integrated operations across North America and Australia, AdvanCell is advancing a pipeline of differentiated precision radiopharmaceuticals designed to improve…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Ally Bridge Group, Alpha Wave, new investors Bain Capital Life Sciences, Fidelity ManagementFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAdvanCell raised $315M Series D, announced 2026-07-15From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersAdvanCell's $315M Series D is a top-decile capital-flow event within Healthcare & Life Sciences, positioning the company among the largest recent rounds in the sector…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
AdvanCell · Financing Record
Explore source-linked visual explanations for AdvanCell. Unsupported claims are withheld while source review continues.
Record 8217 · Recorded date: 2026-07-15
Explore company records →